Hormone replacement therapy in postmenopausal women and its effects on plasma lipid levels

Clinical Chemistry and Laboratory Medicine

Volumn 40, Issue 5, 2002, Pages 446-451

  Erberich, Lúcia C N ^a   Alcântara, Vânia M ^a   Picheth, Geraldo ^a   Scartezini, Marileia ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Coronary heart disease; Estradiol; Estrogens; Lipoproteins; Progestogens; Serum lipids

Indexed keywords

CHOLESTEROL; CONJUGATED ESTROGEN; CYPROTERONE ACETATE; DAIDZEIN; DYDROGESTERONE; EQUOL; ESTRADIOL; ESTROGEN; ESTROGEN DERIVATIVE; GENISTEIN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOFLAVONOID; LEVONORGESTREL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; METHYLTESTOSTERONE; NORETHISTERONE ACETATE; NORGESTREL; PHYTOESTROGEN; PRAVASTATIN; PROGESTERONE; PROGESTERONE DERIVATIVE; RALOXIFENE; SIMVASTATIN; TAMOXIFEN; TIBOLONE;

ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MEDICAL LITERATURE; PATHOGENESIS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; ARTERIOSCLEROSIS; BLOOD; DRUG CONTRAINDICATION; TREATMENT OUTCOME;

ARTERIOSCLEROSIS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LIPIDS; POSTMENOPAUSE; TREATMENT OUTCOME;

EID: 0036283208     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2002.076     Document Type: Article

References (64)

1. Menopause and risk of cardiovascular disease: The Framingham study
2. Increased incidence of coronary heart disease in women castrated prior to the menopause
3. Influence of bilateral oophorectomy upon lipid metabolism
4. Risk factors that attenuate the female coronary disease advantage
5. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study
6. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence
7. Effects of estrogens and progestogens on the lipid profile in post-menopausal hypogonadism
8. Postmenopausal hormone therapy and mortality
9. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
10. Classical risk factors and emerging elements in the risk profile for coronary artery disease
11. Effects of gender and menopausal status on plasma lipoprotein subspecies and particle sizes
12. Atherogenicity of triglyceride-rich lipoproteins
13. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome
14. Influence of the perimenopause on cardiovascular risk factors and symptoms of middle-aged healthy women
15. Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels
16. Low-density lipoprotein subclass patterns and risk of myocardial infarction
17. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor
18. Variations in oxidative susceptibility among six low density lipoprotein subfraction of differing density and particle size
19. Effect of estrogen on the size of low-density lipoprotein particles in posmenopausal women
20. Differential effects of estrogen on low-density lipoprotein subclasses in healthy postmenopausal women
21. Differences in apolipoproteins and low-density lipoprotein subfractions in postmenopausal women on and off estrogen therapy: Results from the Framingham Offspring Study
22. Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in postmenopausal, dyslipidemic women
23. Response of plasma low density lipoprotein subfractions to oestrogen replacement therapy following surgical menopause
24. Change in LDL particle size is associated with change in plasma triglyceride concentration
25. Abnormalities in very low, low, and high density lipoproteins in hypertriglyceridemia: Reversal toward normal with bezafibrate treatment
26. Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes
27. Lipid transfer reactions and lipid composition of low-density lipoprotein particles in postmenopausal women receiving estrogen
28. Changes in LDL density across the menopausal transition
29. Estrogens and lipid metabolism
30. Mechanisms regulating LDL metabolism in subjects on peroral and transdermal estrogen replacement therapy
31. Impact of gender on the metabolism of apolipoprotein A-I in HDL subclasses LpAI and LpAI:AII in older subjects
32. Effects of menopause and hormone replacement therapy on plasma lipids, lipoproteins and LDL-receptor activity
33. Substitutive hormonal treatment of menopause. Effects on lipoprotein metabolism
34. Lp(a) lipoprotein: Relationship to cardiovascular disease risk factors, exercise, and estrogen
35. Metabolism of Apo(a) and ApoB 100 of lipoprotein(a) in women: Effect of postmenopausal estrogen replacement
36. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause
37. Cardiovascular disease risk and hormone replacement therapy (HRT): A review based on randomised, controlled studies in postmenopausal women
38. Current concepts in estrogen replacement therapy in the menopause
39. A mulher pósmenopáusica e as doenças cardiovasculares
40. Oral versus transdermal hormone replacement therapy
41. Clinical equivalence of intranasal and oral 17beta-estradiol for postmenopausal symptoms
42. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women
43. Effects of oestrogens and selective oestrogen receptor modulators on serum lipoproteins and vascular function
44. Effects of the combined hormonal replacement drug estradiol valerate/levonorgestrel on climacteric complaints, endometrium and lipid profile of peri- and postmenopausal women
45. Effects of hormone replacement therapy on the endometrium and lipid parameters: A review of randomized clinical trials, 1985 to 1995
46. Hormone replacement therapy in postmenopausal women with specific risk factors for coronary artery disease
47. The menopause and lipid metabolism: Strategies for cardiovascular disease prevention
48. Caritid intima-media thickness in surgical menopause: Women who received HRT versus who did not
49. Effects of post-menopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: A review
50. Continuous combined and sequential estradiol and norethindrone acetate treatment of post-menopausal women: Effect of plasma lipoproteins in a two-year placebo-controlled trial
51. Long-term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrations
52. Hormone replacement therapy and lipid-lipoprotein concentrations
53. Effects of continuous conjugated estrogen and micronized progesterone therapy upon lipoprotein metabolism in post-menopausal women
54. Lipid effects of hormone replacement therapy with sequential transdermal 17-beta-estradiol and oral dydrogesterone
55. Hormone replacement and simvastatin in the therapy of hypercholesterolemic postmenopausal women
56. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic post-menopausal women
57. Effects of simvastatin only or in combination with continuous combined hormone replacement therapy on serum lipid levels in hypercholesterolaemic post-menopausal women
58. Hormone replacement therapy and cardiovascular disease
59. Estrogen/progesterone replacement versus pravastatin and their sequential association in hypercholesterolemic post-menopausal women
60. Synergistic inhibition of LDL oxidation by phytoestrogens and ascorbic acid
61. Use of androgens in post-menopausal women
62. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles
63. Hormones and sexual function
64. Lipid effects, effectiveness and acceptability of tibolone versus transdermic 17 beta-estradiol for hormonal replacement therapy in women with surgical menopause